Foster & Motley Inc. Sells 22,368 Shares of Pfizer Inc. (NYSE:PFE)

Foster & Motley Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 15.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 122,933 shares of the biopharmaceutical company's stock after selling 22,368 shares during the period. Foster & Motley Inc.'s holdings in Pfizer were worth $3,261,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the fourth quarter valued at $26,000. Gladius Capital Management LP grew its holdings in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 38,015 shares during the last quarter. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter worth about $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer in the third quarter valued at about $35,000. Finally, Joseph Group Capital Management grew its stake in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 771 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PFE. Evercore ISI raised Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday. Guggenheim dropped their target price on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research note on Wednesday, December 11th. Finally, UBS Group lowered their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer has an average rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Trading Up 1.3 %

Shares of NYSE:PFE traded up $0.34 during mid-day trading on Thursday, reaching $26.96. The stock had a trading volume of 13,821,476 shares, compared to its average volume of 34,811,559. The firm has a market cap of $152.75 billion, a PE ratio of 36.43, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm has a 50 day simple moving average of $26.22 and a two-hundred day simple moving average of $27.90. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer's revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.17) EPS. On average, research analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This is a boost from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.38%. Pfizer's dividend payout ratio (DPR) is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.